1976-1990

• Incorporated as a private limited company, Shasun Chemicals in Chennai
• First production facility established at Velachery, Chennai, for manufacture of Analgin (antipyretic).
• Second production facility was established at Puducherry for manufacture of Ibuprofen (anti-inflammatory)

1990-2000

• Third manufacturing unit set up at Cuddalore to manufacture the anti-ulcerative Ranitidine HCI
• Shasun converted into a public limited company, incorporating its present name.
• US subsidiary, Shasun Inc., is established
• The company's shares were listed on Mumbai, Ahmedabad and Chennai stock exchanges.
• Technology and joint marketing agreement signed with Nagase & Co., Japan for S+Ibuprofen
• The company signed a technology agreement with Chircotech, UK, for S+Naproxen.
• The company signed a joint venture agreement with Austin Chemical Company, USA,

2000-2010

• The company's exports exceeded Rs.100 cr.
• Established a biotech laboratory in its R&D centre.
• Signed a letter of intent with Eli Lilly for supply and manufacture of an anti-TB drug.
• Multi Purpose Plant at Cuddalore was commissioned.
• Completed setting up its new Research Centre.
• Strategic partnership with Glenmark and Alpharma(now part of Actavis) for Development & Supply of Formulation products.
• Completed its first ever acquisition of Rhodia Pharma Solutions business marking its advent in the Global supply arena
• Successful maiden inspection of the formulation unit by US FDA authorities in Pondicherry (Puducherry).
• Successful completion of the US FDA inspection of its Cuddalore and UK facilities (Annan and Dudley).
• Received certi?cation of ISO 27001 (ISMS-Information Security Management Systems) by Bureau Veritas.
• Signed a licensing agreement with Gilead for manufacture of Viread to support the Clinton Foundation initiative
• Licensing of cross-coupling technology (Buchwald Technology) to H-Lundbeck A/S and Merck & Co. Inc.
• Setting up of Lab facility at Piscataway (New Jersey), United States to provide API development service in pre-clinical and clinical trial stages.
• Embarks on implementation of an enterprise resource planning (ERP) - SAP across all its locations.
• Successful completion of clinical trials of “Streptokinase”, a biotech product.
• Successful completion of US FDA re-inspection of formulation unit at Puducherry.
• Closure of Annan plant at Scotland, UK and operations consolidated at Dudley facility.
• Commercial Launch of Recombinant Streptokinase in the Indian Market in June 2009.
• Initiation of Toxicity Studies with respect to GCSF and PEG-GCSF - biotech products.
• Received commercial order of a leading API product from an Innovator Company (an anti depressant drug).
• Achieved leadership position in API product - Gabapentin (?nds application for anti epileptic cases).
• Finished Dosages sales has grown by 100% as compared to FY09 and has crossed Rs 50 crores in turnover in FY10.